What fail­ure? Cataba­sis shares soar af­ter ex­ecs tout open-la­bel da­ta, PhI­II plans

Be­fore re­view­ing Cataba­sis’ sec­ond at­tempt at mak­ing a good first im­pres­sion with its Phase II study of the Duchenne mus­cu­lar dy­s­tro­phy drug edasa­lonex­ent (CAT-1004), it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER